Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK
Zheng Liang, Jian Li, Guoliang Zhang, et al.
The Clinical Respiratory Journal (2023) Vol. 17, Iss. 10, pp. 1006-1016
Open Access | Times Cited: 4
Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment
Fouad Attieh, Antoine Chartouni, Marc Boutros, et al.
Immunotherapy (2023) Vol. 15, Iss. 16, pp. 1415-1428
Closed Access | Times Cited: 4
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol
Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review
Safa Can Efil, Burak Bi̇lgi̇n, Furkan Ceylan, et al.
Journal of Oncology Pharmacy Practice (2024) Vol. 30, Iss. 7, pp. 1214-1239
Closed Access | Times Cited: 1
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
Bolun Zhou, Fan Zhang, Wei Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e009355-e009355
Open Access | Times Cited: 1
Perioperative Immuntherapie beim operablen Lungenkarzinom: aktuelle Studienlage und neue Therapiestandards
Uyen‐Thao Le, Birte Ohm, Severin Schmid
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie (2024) Vol. 149, Iss. S 01, pp. S35-S44
Closed Access | Times Cited: 1
Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer
Shuta Ohara, Kenichi Suda, Akira Hamada, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 31, pp. 2229-2234
Open Access | Times Cited: 1
Perioperative immunotherapy for nonsmall cell lung cancer
Jingya Huang, Wenyuan Li, Hui Guo
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Prognosis prediction using significant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors: a meta-analysis
Fang Nie, Ying Wang, Wanting Shi, et al.
Frontiers in Surgery (2024) Vol. 11
Open Access | Times Cited: 1
Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
Wenhao Ji, Youhua Jiang, Yuetong Li, et al.
Neoplasma (2024) Vol. 71, Iss. 01, pp. 88-97
Open Access
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy
Sabina Berezowska, Mark Keyter, Hasna Bouchaab, et al.
Advances in Anatomic Pathology (2024) Vol. 31, Iss. 5, pp. 324-332
Open Access
Immune checkpoint inhibition in early-stage non-small cell lung cancer
Kristof Cuppens, Bert Du Pont, J. Knegjens, et al.
Lung Cancer (2024) Vol. 193, pp. 107855-107855
Open Access
Neoadjuvant therapy bridging percutaneous coronary intervention (PCI) and video-assisted thoracoscopic (VATS) lobectomy: a retrospective study
L. Guo, Songlei Ou, Shaoyan Zhang, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 6, pp. 2662-2673
Open Access
Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy
Min Zhang, Liang Zhu, Sibei Liang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Perioperative Immuntherapie beim operablen Lungenkarzinom: aktuelle Studienlage und neue Therapiestandards
Uyen‐Thao Le, Birte Ohm, Severin Schmid
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 09, pp. 604-613
Closed Access
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
M. Mayenga, Ana Rita Pedroso, Marion Ferreira, et al.
Breathe (2024) Vol. 20, Iss. 3, pp. 240044-240044
Open Access
AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
Lei‐Lei Wu, Wen-Mei Jiang, Zhiyuan Liu, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience
Christopher Cronin, Shahid Iqbal, Abdul Rehman Farooq, et al.
Lung Cancer Management (2023) Vol. 12, Iss. 1
Open Access
Nivolumab bei resektablem Bronchialkarzinom

Pneumologie (2023) Vol. 77, Iss. 05, pp. 263-264
Closed Access
Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
Paul R. Walker
Journal of Thoracic Disease (2023) Vol. 15, Iss. 7, pp. 3533-3537
Open Access
Nivolumab bei resektablem Bronchialkarzinom
Susanne Meinrenken
TumorDiagnostik & Therapie (2023) Vol. 44, Iss. 06, pp. 373-374
Closed Access
Early outcomes of minimally invasive surgery versus thoracotomy for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a multi-center propensity score- matched study
Hanbo Pan, Hang Chen, Zhen Ge, et al.
Research Square (Research Square) (2023)
Open Access
A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial
S. S. Mao, Samuel Rosner, Patrick M. Forde, et al.
Clinical Lung Cancer (2023)
Open Access
Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
Hengxing Gao, Xuexue Zou, Jing Wang, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 10, pp. 5307-5318
Open Access
Previous Page - Page 2

Scroll to top